نتائج البحث

1

Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)

المؤلفون: Jianying Zhou, Caicun Zhou, Zhehai Wang, Chengping Hu, Wen Zhang, Dingzhi Huang, Lianke Liu, H. Zhao, Shundong Cang, Jianxin Xue, Chengzhi Zhou, Jian Fang, Li Zhang, Gongyan Chen, Zhixiong Yang, Ping Sun, Min Fan, Hui Zhou, Juan Li, Jiuwei Cui, Lin Wu, Baolan Li, Yingying Du, Yun Fan, Yuping Li, Shuyan Wang

المصدر: Journal of Thoracic Oncology. 16:1501-1511

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::ae08ff7166f291e1979183f19d3e976cTest
https://doi.org/10.1016/j.jtho.2021.04.011Test

2

Pretreatment to Posttreatment Hypoxia Inducible Factor-1α Ratios as a Potentially Predictive Marker for First-Line Treatment in Nonsmall Cell Lung Cancer Patients without Known Driver Mutations

المؤلفون: Tongmei Zhang, Qunhui Wang, Fanbin Hu, Baolan Li, Jie Li, Hongmei Zhang, Mingming Hu, Meng Gu, Yuan Yang

المصدر: Genetic Testing and Molecular Biomarkers. 24:798-803

مصطلحات موضوعية: Adult, Male, Vascular Endothelial Growth Factor A, Lung Neoplasms, Organoplatinum Compounds, Angiogenesis, medicine.medical_treatment, Kaplan-Meier Estimate, Pemetrexed, Adenocarcinoma, chemistry.chemical_compound, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, Humans, Medicine, Prospective Studies, Genetics (clinical), Aged, Proportional Hazards Models, Chemotherapy, Vascular Endothelial Growth Factor Receptor-1, Predictive marker, Neovascularization, Pathologic, business.industry, Smoking, General Medicine, Middle Aged, Hypoxia (medical), Hypoxia-Inducible Factor 1, alpha Subunit, Vascular Endothelial Growth Factor Receptor-2, Progression-Free Survival, Endostatins, Neoplasm Proteins, Bevacizumab, First line treatment, Vascular endothelial growth factor, Treatment Outcome, ROC Curve, Hypoxia-inducible factors, chemistry, Area Under Curve, Cancer research, Cytokines, Female, Taxoids, Non small cell, medicine.symptom, business, Follow-Up Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53d77b8346fe56e6153fc00edf53b997Test
https://doi.org/10.1089/gtmb.2020.0173Test

3

Effect of anlotinib as a third‐ or further‐line therapy in advanced non‐small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial

المؤلفون: Weiqiang Chen, Xiuwen Wang, Kejun Nan, Li Zhang, Jianxing He, Baohui Han, Jing Zhu, Zhehai Wang, Kai Li, Baolan Li, Faguang Jin, Qiming Wang, Yi Luo, Ying Cheng, Jianhua Shi, Yuankai Shi

المصدر: Cancer Medicine, Vol 9, Iss 8, Pp 2621-2630 (2020)
Cancer Medicine

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85c71178d0f1b1011129c0a59a412f98Test
https://doaj.org/article/d4fedd9759804f7bb2adee9ef4881b82Test

4

Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study

المؤلفون: Christoph Mancao, Yong Song, Weimin Li, Jifeng Feng, Jian Fang, Wenfeng Fang, Bo Peng, Zhixiong Yang, Shundong Cang, Qitao Yu, Zhehai Wang, Hui Zhou, Jianying Zhou, Gongyan Chen, Juan Li, Xiaodong Mei, Luyao Sun, Jiya Sun, Oscar Puig, Li Zhang, Shuyan Wang, Rui Zhou, Rui Ma, Xiubao Ren, M. Bi, You Lu, Baohui Han, Yunpeng Yang, Zhiyong He, Wei Xu, Baolan Li

المصدر: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 16(12)

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de7ce8bbbf8321308b8a04bc581ada8cTest
https://pubmed.ncbi.nlm.nih.gov/34358724Test

5

VP9-2021: ORIENT-31: Phase III study of sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated nonsquamous NSCLC who progressed after EGFR-TKI therapy

المؤلفون: Ke Wang, Yueyin Pan, A. Liu, Li Xuyan, Shun Lu, L. Han, L. Miao, Jiuwei Cui, Qian Wang, Baolan Li, Yali Hu, Zhenghang Wang, Lingqian Wu, M. Sun, S. Cang, Yung-Chi Cheng, Hong Jian, Cuimin Ding, Jingyun Fang, Feng Ye

المصدر: Annals of Oncology. 33:112-113

مصطلحات موضوعية: Oncology, medicine.medical_specialty, Chemotherapy, Egfr tki, business.industry, medicine.medical_treatment, Internal medicine, medicine, In patient, Hematology, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::60d3551b03e7599171f48ea844501b37Test
https://doi.org/10.1016/j.annonc.2021.10.007Test

6

Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer

المؤلفون: Zhehai Wang, Yi Luo, Kai Li, Weiqiang Chen, Baolan Li, Yinlan Chen, Yin Cheng, Xiaoyan Si, Hanping Wang, Faguang Jin, Jianhua Shi, Jianying Zhou, Xiuwen Wang, Xiaotong Zhang, Li Zhang, Donglin Wang, Jianxing He, Mengzhao Wang, Kejun Nan, Yuankai Shi, Baohui Han, Qiming Wang

المصدر: Lung Cancer. 122:32-37

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Pulmonary and Respiratory Medicine, Cancer Research, medicine.medical_specialty, Indoles, Lung Neoplasms, Constipation, medicine.medical_treatment, Antineoplastic Agents, Placebo, Targeted therapy, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Double-Blind Method, Quality of life, Carcinoma, Non-Small-Cell Lung, Surveys and Questionnaires, Internal medicine, medicine, Humans, Lung cancer, Aged, Neoplasm Staging, Chemotherapy, business.industry, Cancer, Middle Aged, Placebo Effect, medicine.disease, Survival Analysis, humanities, Clinical trial, Treatment Outcome, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Quality of Life, Quinolines, Female, medicine.symptom, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::366fa91fcfbcbe6f96bd4465e39033d1Test
https://doi.org/10.1016/j.lungcan.2018.05.013Test

7

Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)

المؤلفون: You Lu, Conghua Xie, Zhehai Wang, Xiaodong Mei, Baohui Han, Zhixiong Yang, Donglei Zhu, Jianying Zhou, M. Bi, Baolan Li, Lijun Wang, Wen Zhang, Nong Yang, Yunpeng Yang, Yong Song, Weimin Li, Zhiyong He, Ying Cheng, Shuyan Wang, Rui Ma, Juan Li, Zhuang Yu, Xiubao Ren, Yan Zhang, Qitao Yu, Jian Fang, Jifeng Feng, Rui Zhou, Yanqiu Zhao, Li Zhang, Hui Zhou, Shundong Cang, Gongyan Chen, Yingyi Wang

المصدر: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 15(10)

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b99d8e9dc5d07cd3f270abd0b55d3e84Test
https://pubmed.ncbi.nlm.nih.gov/33246599Test

8

The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial

المؤلفون: Zhen He, Xiuwen Wang, Yan Sun, Yuankai Shi, Ying Cheng, Weiqiang Chen, Zhehai Wang, Jian Dong, Baohui Han, Li Zhang, Faguang Jin, Shaomei Li, Hong Tang, Jianxing He, Yufeng Wu, Lili Wang, Kai Li, Baolan Li, Sen Yang, Kejun Nan, Jianhua Shi, Yi Luo, Qiming Wang, Lin Wu

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f564b93a3be3b4a0458ac08918b4ac19Test
https://europepmc.org/articles/PMC6835105Test/

9

Vimentin expression in circulating tumor cells (CTCs) associated with liver metastases predicts poor progression-free survival in patients with advanced lung cancer

المؤلفون: Li Tong, Baolan Li, Peter Lin, Yanxia Liu, Yuan Gao, Fanbin Hu, Ying Wang, Tongmei Zhang, Lina Zhang

المصدر: Journal of Cancer Research and Clinical Oncology

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, medicine.medical_specialty, Lung Neoplasms, medicine.medical_treatment, Aneuploidy, Vimentin, 03 medical and health sciences, 0302 clinical medicine, Circulating tumor cell, Internal medicine, Medicine, Humans, Progression-free survival, Prospective Studies, Lung cancer, Advanced lung cancer, Chemotherapy, Hematology, biology, business.industry, Hazard ratio, Liver Neoplasms, Circulating tumor cells, Aneuploidy of Chr8, General Medicine, Middle Aged, medicine.disease, Neoplastic Cells, Circulating, Cell size, 030104 developmental biology, 030220 oncology & carcinogenesis, biology.protein, Female, business, Original Article – Cancer Research, Chromosomes, Human, Pair 8, Follow-Up Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3831389043a7c73f457e795bec09dec7Test
https://pubmed.ncbi.nlm.nih.gov/31646374Test

10

Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment

المؤلفون: Jianhua Shi, Xiuwen Wang, Hao Yu, Yang Zhao, Ying Cheng, Baohui Han, Jian Dong, Yi Luo, Qiming Wang, Zhehai Wang, Weiqiang Chen, Li Zhang, Yuankai Shi, Jing Wang, Kejun Nan, Yizhuo Zhao, Kai Li, Baolan Li, Faguang Jin, Jianxing He, Zhujun Liu

المصدر: Cancer Biology & Medicine
Cancer Biology & Medicine, Vol 15, Iss 4, Pp 443-451 (2018)

مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, medicine.drug_class, medicine.medical_treatment, lcsh:RC254-282, Tyrosine-kinase inhibitor, 03 medical and health sciences, 0302 clinical medicine, Growth factor receptor, Non-small cell lung cancer, Internal medicine, medicine, anlotinib, Chemotherapy, business.industry, Proportional hazards model, third- or further-line therapy, Hypertriglyceridemia, prognostic factor analysis, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Elevated alkaline phosphatase, 030104 developmental biology, 030220 oncology & carcinogenesis, Original Article, Anlotinib Hydrochloride, medicine.symptom, business, Progressive disease

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b43346061a6393ae4a27f6a40e7e038Test
http://europepmc.org/articles/PMC6372914Test

تنقيح النتائج